Bolt Biotherapeutics, Inc. financial data

Symbol
BOLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 Chesapeake Drive, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Bolt Therapeutics, Inc. (to 5/7/2015)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 408 % -39.6%
Debt-to-equity 49.1 % +38.9%
Return On Equity -79.1 % -54.5%
Return On Assets -53 % -40.3%
Operating Margin -950 % +1.81%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.3M shares +0.56%
Common Stock, Shares, Outstanding 38.3M shares +0.59%
Entity Public Float 21.9M USD -31.8%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 38.2M shares +0.98%
Weighted Average Number of Shares Outstanding, Diluted 38.2M shares +0.98%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 7.69M USD -2.36%
Research and Development Expense 57.5M USD -6.62%
General and Administrative Expense 18.5M USD -18.1%
Operating Income (Loss) -73M USD +4.13%
Nonoperating Income (Expense) 9.93M USD +41.9%
Net Income (Loss) Attributable to Parent -63.1M USD +8.79%
Earnings Per Share, Basic -1.65 USD/shares +9.84%
Earnings Per Share, Diluted -1.65 USD/shares +9.84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.21M USD -33.3%
Cash, Cash Equivalents, and Short-term Investments 70.2M USD -45.4%
Assets, Current 50.8M USD -51.9%
Property, Plant and Equipment, Net 3.14M USD -36.7%
Operating Lease, Right-of-Use Asset 21.8M USD +13.8%
Other Assets, Noncurrent 62K USD -96.6%
Assets 99.6M USD -37.6%
Accounts Payable, Current 1.51M USD -49.5%
Employee-related Liabilities, Current 4.2M USD -27.8%
Liabilities, Current 15.9M USD -22.5%
Operating Lease, Liability, Noncurrent 23M USD +31.7%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 42.4M USD -9.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 97K USD +162%
Retained Earnings (Accumulated Deficit) -427M USD -17.3%
Stockholders' Equity Attributable to Parent 57.2M USD -49.3%
Liabilities and Equity 99.6M USD -37.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.8M USD +28.4%
Net Cash Provided by (Used in) Investing Activities 10.2M USD -64.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 38.3M shares +0.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.55M USD -217%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.97M USD -28.7%
Deferred Tax Assets, Valuation Allowance 96.9M USD +15.8%
Deferred Tax Assets, Gross 103M USD +15.3%
Operating Lease, Liability 25.2M USD +24.7%
Depreciation 1.8M USD -5.26%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -63.1M USD +7.6%
Lessee, Operating Lease, Liability, to be Paid 36.6M USD +24%
Property, Plant and Equipment, Gross 10.4M USD -2.73%
Operating Lease, Liability, Current 2.25M USD -19.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.4M USD +24.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.12M USD +4.83%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +9.01%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.4M USD +22.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.58M USD +60.3%
Deferred Tax Assets, Operating Loss Carryforwards 53.5M USD +13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 23.8M USD +27.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.78M USD +60.3%
Operating Lease, Payments 1.2M USD +3.36%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 458K USD -1.93%
Deferred Tax Assets, Net of Valuation Allowance 6.51M USD +8.79%
Share-based Payment Arrangement, Expense 7.41M USD -19.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%